Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers

Dr. Mukesh Nandave is an In-charge Director of the School of Pharmaceutical Sciences, Associate Dean (Research), and head of the Department of Pharmacology and Pharmaceutical Biotechnology at Delhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, New Delhi, India. He has earlier served as associate professor and head of the Department of Pharmacology at NMIMS University, Mumbai (2010-2017). He has also worked as a research scientist in the Medical Affairs and Clinical Research Department of Ranbaxy Research Laboratories (currently known as Sun Pharmaceutical Industries Limited, Gurugram). Dr. Nandave earned his Ph. D. in pharmacology from AIIMS, Delhi and received his post-doctoral training from the Division of Cardiothoracic Surgery, the Ohio State University Medical Center, Columbus, USA.For more than 20 years, Dr. Nandave has investigated the role of nutraceuticals, herbomineral formulations, and phytoconstituents for myocardial ischemia & reperfusion injury, diabetes, obesity, and pain management. His lab received more than 3.5 crore total funding from Govt. (DBT, DST, ICMR, and AYUSH) as well as industry (Pharmazz, Dabur, Fertis India, Charak Pharma, Madhavbaug, and Sandu Pharma). He has published over 100 papers in peer-reviewed national and international journals, books, and book chapters.Dr. Nandave has received numerous awards including the Distinguished Leadership Award of International Academy of Cardiovascular Sciences; Prof. S. C. Lahiri Oration and G. Achari Gold Medal by Indian Pharmacological Society; Association of Pharmaceutical Teachers of India (APTI) Young Pharmacy Teacher of the Year Award, Early Investigator Award by International Society for Heart Research, Prof. Duggirala Visweswaram & Prof. Sreemantula Satyanarayana Prize; Best Research Output of the Year for 2014-2015, 2013-2014, and 2012-2013 Award" of SVKM's NMIMS University.Dr. Nandave is secretary general, of the International Academy of Cardiovascular Sciences (IACS)-India section and treasurer of the Society for Promotion and Research of Cardiovascular Sciences (SPARCS). He is a life member of various professional bodies including the International Society for Heart Research (ISHR), the International Academy of Cardiovascular Sciences (IACS); the Indian Pharmacological Society (IPS); the Indian Pharmaceutical Association (IPA); the Association of Physiologist and Pharmacologist of India (APPI); Association of Pharmaceutical Teachers of India (APTI); and Society for Ethnopharmacology.

• Chapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS).- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders.- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs).- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin–angiotensin system.- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients.- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure.- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients.- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease.- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients.- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.